메뉴 건너뛰기




Volumn 121, Issue 12, 2011, Pages 4621-4623

A new medical therapy for cushing disease?

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

EID: 84055200220     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61127     Document Type: Note
Times cited : (4)

References (10)
  • 2
    • 58149389462 scopus 로고    scopus 로고
    • The medical treatment of Cushing's disease: Effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery
    • Pivonello R, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223-230.
    • (2009) J Clin Endocrinol Metab , vol.94 , Issue.1 , pp. 223-230
    • Pivonello, R.1
  • 3
    • 58149383820 scopus 로고    scopus 로고
    • Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial
    • Boscaro M, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115-122.
    • (2009) J Clin Endocrinol Metab , vol.94 , Issue.1 , pp. 115-122
    • Boscaro, M.1
  • 4
    • 84055217296 scopus 로고    scopus 로고
    • EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
    • Fukuoka H, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121(12):4712-4721.
    • (2011) J Clin Invest , vol.121 , Issue.12 , pp. 4712-4721
    • Fukuoka, H.1
  • 6
    • 46749144174 scopus 로고    scopus 로고
    • Mechanisms of resistance to ErbB-targeted cancer therapeutics
    • DOI 10.1172/JC136260
    • Wang Q, Greene MI. Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest. 2008;118(7):2389-2392. (Pubitemid 351949768)
    • (2008) Journal of Clinical Investigation , vol.118 , Issue.7 , pp. 2389-2392
    • Wang, Q.1    Greene, M.I.2
  • 7
    • 0030064976 scopus 로고    scopus 로고
    • Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness
    • DOI 10.1210/jc.81.2.656
    • LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab. 1996;81(2):656-662. (Pubitemid 26055681)
    • (1996) Journal of Clinical Endocrinology and Metabolism , vol.81 , Issue.2 , pp. 656-662
    • LeRiche, V.K.1    Asa, S.L.2    Ezzat, S.3
  • 8
    • 3042530932 scopus 로고    scopus 로고
    • Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas
    • DOI 10.1038/modpathol.3800118
    • Onguru O, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol. 2004;17(7):772-780. (Pubitemid 38843359)
    • (2004) Modern Pathology , vol.17 , Issue.7 , pp. 772-780
    • Onguru, O.1    Scheithauer, B.W.2    Kovacs, K.3    Vidal, S.4    Jin, L.5    Zhang, S.6    Ruebel, K.H.7    Lloyd, R.V.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.